DOW JONES21,052.53-360.91 -1.69%
S&P 5002,488.65-38.25 -1.51%
NASDAQ7,373.08-114.23 -1.53%

Goldman Sachs Initiates Coverage On Momenta Pharmaceuticals with Neutral Rating, Announces $29 Price Target

Goldman Sachs analyst Graig Suvannavejh initiates coverage on Momenta Pharmaceuticals (NASDAQ:MNTA) with a Neutral rating and a $29 price target.

Benzinga · 03/12/2020 09:27

Goldman Sachs analyst Graig Suvannavejh initiates coverage on Momenta Pharmaceuticals (NASDAQ:MNTA) with a Neutral rating and a $29 price target.